Immune recovery of middle-aged HIV patients following antiretroviral therapy – an observational cohort study
(Adapted from Medicine: July 2017 - Volume 96 - Issue 28 - p e7493)

ABSTRACT

In HIV infected persons, age is negatively associated with optimal CD4 recovery following antiretroviral therapy. Our understanding of the situation in older adults, especially the middle-aged, is however limited. We undertook to examine the latter’s pattern of CD4/CD8 recovery following antiretroviral therapy.

Retrospective clinical cohort data of HIV patients diagnosed between 1985 and 2014 in Hong Kong were collected. They were categorised by age at treatment initiation, viz., young adults (age 18-49), middle-aged (age 50-64) and elderly (≥65 years old). Predictors of immune recovery (CD4 count, CD8 count, CD4/CD8 ratio) over time were examined using multivariable linear generalized estimating equations.

A total of 2754 patients (aged≥18) have been on antiretroviral therapy, with baseline characteristics similar between middle-aged and the elderly. Late diagnosis, defined as progression to AIDS within 3 months of HIV diagnosis, was less common in middle-aged (OR=0.58, 95%C.I.=0.37-0.91). Among Chinese patients who have been on treatment for ≥4 years (n=913), 80.6%, 14.6% and 4.8% were young adults, middle-aged and elderly respectively. Late treatment initiation, defined as AIDS diagnosis or CD4 count ≤100cells/μL before treatment, was common in middle-aged and elderly, the former however had faster CD4 recovery (3.95 vs 3.36 cells/μL/month), but slower CD8 decline (-1.76 vs -4.34 cells/μL/month) and CD4/CD8 normalisation (0.009 vs 0.0101/month).

As a transitional age group, the immune recovery of middle-aged patients lagged behind young adults largely because of late treatment initiation. Following adoption of early and non-CD4 guided treatment initiation, their long term clinical outcome is expected to improve.

Introduction

Clinically, age is an important predictor of clinical outcome after antiretroviral therapy in HIV patients, as observed in a number of studies. Compared with younger patients, older adults had poorer CD4 recovery after highly active antiretroviral therapy (HAART) initiation, higher mortality and co-morbidity rate. On the other hand, due to poor retention in care in young patients, the risk of viral rebound, virological failure and immunological failure was higher in younger than older patients. It is clear that the final clinical outcome is dependent not just on the rate and extent of one’s immunological recovery, but also factors associated with good adherence to and tolerability of prescribed HAART regimens. Their association with clinical outcomes are both age-dependent. As HAART is lifelong treatment, an increasing proportion of older adults is anticipated to be on treatment in the coming years. This poses a challenge in the monitoring of immunological outcome of patients across all ages, as attention may be needed on factors which are age associated.
As a sexually acquired infection, HIV affects largely sexually active young adults at the time of virus transmission. Since there’s often a time lag between infection and diagnosis, and from diagnosis and to treatment initiation, a proportion of HIV infected young adults might have entered their middle age when therapy begins. Arbitrarily defining ‘middle-age’ as the age band between 50 and 64 years old, these persons constitute a unique group transiting from young to old. Their immune outcome might be affected by a mix of factors related to both younger and older-aged individuals, including poor retention in care rate, delayed HIV diagnosis, aging and other factors. In previous studies, patients were conventionally categorized with a cut-off of 50, 55 and 60 years old for the elderly, while middle-aged group was subsumed under either younger or older-aged category. A study in South Africa compared adults aged 25-54 and aged ≥55 years, revealing that patients aged ≥55 years old had lower CD4 recovery rate 6 months after HAART initiation, even though they had better viral suppression. Another study has included 50-59 years old and ≥60 years old as two out of five age groups, showing positive association between age at HAART initiation and poor clinical outcomes and mortality. In either circumstance, however, the immune outcome of middle-aged HIV patients has not been specifically addressed.

In planning this study, we hypothesized that middle-aged HIV patients constitute a distinct group whose immunological recovery following HAART could outperform the elderly despite their similar baseline characteristics, on the ground that they could benefit from earlier treatment initiation, comparable to the younger patients. As older patients were more likely to be late for treatment, early initiation of HAART for the middle-aged would advance their treatment start-date to match with that of young adults, whose immunological recovery should be superior to the other 2 groups. To prove this hypothesis, we examined the immune recovery of middle-aged HIV patients in a clinical cohort in Hong Kong, where standard HAART regimens have been offered in accordance with established protocols. They were compared with young adults and the elderly followed up under the same protocols. We used 3 markers – CD4, CD8 and CD4/CD8 ratio – to study the immunological change after HAART initiation, and examine their associations with the timing of treatment initiation.

Methods

We accessed anonymous longitudinal clinical data (by 2014) of all HIV patients attending Integrated Treatment Centre, the largest HIV specialist clinic serving over half of the HIV caseload in Hong Kong. HIV patients are followed-up at 3-4 months’ interval in accordance with protocol (http://www.hivmanual.hk/) modelled on international guidelines. Patients aged 18 or above at diagnosis were included in this study. Data retrieved included CD4, CD8, CD4/CD8 ratio and viral load measurements at each follow-up time point, baseline socio-demographics (including gender, ethnicity, route of transmission), condition at diagnosis (age, HIV subtype, Cytomegalovirus (CMV) serology) and pre-treatment (age, interval from diagnosis to treatment initiation), regimen prescribed with records of start and end date, and AIDS diagnosis. With reference to our previous studies, we classified patients by 3 age categories: 18-49 (young adults), 50-64 (middle-aged), and ≥65 (elderly) years old. Using simple logistic regression models, we compared the characteristics between young adults and middle-aged, and between middle-aged and elderly.

In Hong Kong, a CD4 guided approach to treatment initiation was in place during the period when cohort subjects were diagnosed and therefore included in this study. To examine factors associated with late treatment initiation, we performed univariate analysis. With reference to previous study, we defined late treatment initiation as patients with very low pre-treatment CD4 count (≤100cells/µL) or AIDS diagnosis before treatment initiation. We used CD4 level ≤100/µL instead of <200/µL as the cut-off since 74% of our patients were Chinese, whose CD4 level was generally lower than the White in the general population.
Patients who were not initiated on treatment or without pre-treatment CD4 level were excluded.

To study immune recovery after HAART initiation, we selected patients who were Chinese, treatment naïve, had been on treatment for ≥4 years, and had ever achieved viral load suppression (≤500 copies/mL) within 4 years of treatment for further analysis. We examined their CD4, CD8 and CD4/CD8 ratio over time to evaluate their immune recovery, and analysed them separately as outcomes in multivariable linear generalized estimating equations (GEE) with unstructured working correlation matrix. Measurements between month -2 and month 60 were included. Variables including time (months from treatment initiation), age category, gender, late HIV diagnosis (i.e. AIDS diagnosis within 3 months from HIV diagnosis), late treatment initiation (yes vs no), baseline CMV serology (positive vs negative), regimen (2 nucleoside reverse-transcriptase inhibitors (NRTI) plus a third compound: either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or antiretroviral other than NNRTI) and months from diagnosis to treatment initiation were examined in the model. To examine the interactions between time, age category and late treatment initiation, we have added and dropped all combinations of these three variables with other variables in GEE models. Final GEE model for each immune marker was selected by the inclusion of significant predictors by manual stepwise backward approach. All statistical analyses were performed in IBM SPSS Statistics 21. P-value <0.05 was considered statistically significant. Complete case analyses were performed.

We obtained data access approval from the Department of Health, Hong Kong Special Administrative Region Government in compliance with the Personal Data (Privacy) Ordinance. Ethical approval was obtained from the Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee (CREC). Individual consent for this study was waived.

**Results**

As of the end of 2014, 3702 HIV patients have visited the clinic for clinical consultation. At diagnosis, 3674 patients were aged 18 or above (median age=35, interquartile range (IQR) = 28-43. By data collection end point, 75% (2754/3674) have initiated treatment, while 26% (832/3205) of the young adults, 19% (66/352) of the middle-aged and 19% (22/117) of the elderly (defining by age at diagnosis) have not yet been started on treatment. We analysed 2754 patients on treatment (19190 persons-years follow-up) in this study. Among them, 2187 (79%) were Chinese, some 43% (928/ 2154 ) were infected with subtype CRF_01AE and 40% (867/2154) subtype B, while 31% (799/ 2540) and 38% (990/2591) had pre-treatment CD4 ≤100/μL and had late treatment initiation respectively. The median number of months from diagnosis to treatment initiation was 6.82 (IQR=2.10-31.23), and the median treatment duration was 62.19 months (IQR=28.93-111.79).
Pre-treatment status by age category

Among patients who had ever been on HAART, we compared their baseline characteristics by age category. At treatment initiation, 2317 (84%) were young adults, 329 (12%) were middle-aged, while 108 (4%) were elderly. The middle-aged were significantly different from young adults in that they were composed of a higher proportion of heterosexually acquired infections and ethnic Chinese. They were more likely to have lower CD4 levels at diagnosis and at treatment initiation, and presented with AIDS before treatment initiation. (Table 1) More were in late treatment initiation but less likely to have >6 months’ interval from diagnosis to treatment initiation. However, there was no significant difference between middle-aged and elderly, except that the former were less likely to be in late diagnosis, were heterosexuals, and had AIDS before treatment initiation.

Factors associated with late treatment initiation in Chinese patients

Among 2754 patients, 2070 were Chinese and had pre-treatment CD4 count for defining late treatment initiation and otherwise. A total of 772 out of 2070 (37%) Chinese patients were classified as having been late in treatment initiation. Middle-aged and elderly at diagnosis (crude odds ratio, OR=1.88, 95%CI=1.44-2.46 for middle-aged; OR=2.48,
Continuing Education (iCE) on HIV/AIDS
Special Preventive Programme, Department of Health

95% CI of 1.62-3.81 for elderly) and at treatment initiation (OR=1.85, 95% CI=1.43-2.39 for middle-aged; OR=2.15, 95% CI=1.43-2.22 for elderly), heterosexually acquired infections (OR=3.05, 95% CI=2.53-3.67) or injection drug use (IDU) (OR=1.02, 95% CI=0.59-1.76) were associated with late treatment initiation. (Table 2) From 2012 onwards (OR=0.29, 95% CI=0.23-0.36), fewer patients were in late treatment initiation. Overall, patients with a long interval from diagnosis to treatment initiation (OR=0.99, 95% CI=0.99-0.99) were less likely to be late for treatment initiation. Among patients with late initiation, however, 68% of them had started treatment within 6 months from HIV diagnosis.

Table 2 Comparison between Chinese patients with and without late treatment initiation (n=2070).

<table>
<thead>
<tr>
<th></th>
<th>Late (n=772)</th>
<th>Crude odds ratio (OR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>freq.</td>
<td>%</td>
<td>freq. %</td>
</tr>
<tr>
<td>Male sex</td>
<td>1159</td>
<td>89%</td>
</tr>
<tr>
<td>Median age at diagnosis (QR)</td>
<td>34.66</td>
<td>28.15-42.78</td>
</tr>
<tr>
<td>Young adults (18-49 y)</td>
<td>1135</td>
<td>87%</td>
</tr>
<tr>
<td>Middle-aged (50-64 y)</td>
<td>124</td>
<td>10%</td>
</tr>
<tr>
<td>Elderly (65 y)</td>
<td>39</td>
<td>3%</td>
</tr>
<tr>
<td>Mode of transmission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSM</td>
<td>847</td>
<td>66%</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>400</td>
<td>31%</td>
</tr>
<tr>
<td>Injection drug use</td>
<td>35</td>
<td>3%</td>
</tr>
<tr>
<td>Others</td>
<td>9</td>
<td>1%</td>
</tr>
<tr>
<td>Gynomediators (CMF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=1298)</td>
<td>69%</td>
<td></td>
</tr>
<tr>
<td>CD4 at diagnosis (cells/μL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤100</td>
<td>17</td>
<td>1%</td>
</tr>
<tr>
<td>101-200</td>
<td>153</td>
<td>12%</td>
</tr>
<tr>
<td>201-500</td>
<td>511</td>
<td>36%</td>
</tr>
<tr>
<td>501-600</td>
<td>355</td>
<td>27%</td>
</tr>
<tr>
<td>&gt;600</td>
<td>262</td>
<td>20%</td>
</tr>
<tr>
<td>Median months from diagnosis to treatment initiation (QR)</td>
<td>11.2</td>
<td>3.02-32.53</td>
</tr>
<tr>
<td>≥6 mo</td>
<td>730</td>
<td>61%</td>
</tr>
<tr>
<td>Median year of treatment initiation (QR)</td>
<td>2011</td>
<td>2007-2013</td>
</tr>
<tr>
<td>≥2012</td>
<td>546</td>
<td>42%</td>
</tr>
<tr>
<td>Median age at treatment initiation (QR)</td>
<td>37.02</td>
<td>30.19-44.94</td>
</tr>
<tr>
<td>Young adults (18-49 y)</td>
<td>1111</td>
<td>86%</td>
</tr>
<tr>
<td>Middle-aged (50-64 y)</td>
<td>140</td>
<td>11%</td>
</tr>
<tr>
<td>Elderly (65 y)</td>
<td>47</td>
<td>4%</td>
</tr>
</tbody>
</table>

1. Patients with pretreatment CD4 level ≤100 cells/μL or AIDS diagnosis before treatment initiation.

Immune recovery following HAART in Chinese patients

The impacts of age and late treatment initiation on immune recovery were examined in GEE models. A total of 913 Chinese patients who had been on treatment for ≥4 years were included in this part of the study. A total of 14502 CD4 measurements, 14490 CD8 measurements and 14490 CD4/CD8 ratio measurements from month -2 to month 60 were included in the analysis. Among them, 736 (80.6%) were young adults, 133 (14.6%) were middle-aged and 44 (4.8%) were elderly. The median treatment duration was 101.5 months (IQR=74.26-139.47 months). The level of CD4, CD8 and CD4/CD8 ratio across time from HAART initiation varied between age categories (Figure 1a-c).

The monthly rate of CD4 recovery after treatment initiation was 4.96 cells/μL. Adding age as a variable and its interaction with time, the monthly CD4 recovery rate was 5.26 cells/μL for young adults, 3.95 cells/μL for middle-aged and 3.36 cells/μL for elderly. Patients not on NNRTI regimen, in late diagnosis, with late treatment initiation, and shorter interval from diagnosis to treatment initiation had lower baseline CD4 level than their counterparts. However, monthly CD4 recovery was faster over time among patients in regimen with antiretroviral other than NNRTI, in late treatment initiation and longer interval
from diagnosis to treatment initiation. In the GEE model for CD4 recovery (model CD4 in Table 3), patients with late treatment initiation had much lower baseline CD4 level than their counterparts, while patients in late HIV diagnosis had higher baseline CD4 level than those not in late HIV diagnosis, after adjusting other variables in the same model. In addition, while CD4 recovery rate among the late treatment initiation group varied significantly by age category, the recovery rate in non-late initiation patients was similar. CD4 recovery among elderly with late treatment initiation was 3.24 cells/μL/month, middle-aged 4.18 cells/μL/month, while young adults was 5.7 cells/μL/month.

Different from CD4 recovery, decline of CD8 count is considered a desirable outcome. In Chinese patients on HAART, their CD8 declined at a rate of 0.89 cells/μL/month since treatment initiation. Age category was a significant predictor of CD8 change across time, with -0.50 cells/μL/month in young adults, -1.76 cells/μL/month in middle-aged and -4.34 cells/μL/month in elderly. It is noted that baseline CD8 for elderly was much higher than young adults. Patients who were male, positive baseline CMV positivity and regimen with antiretroviral other than NNRTI were associated with higher baseline CD8 level. Also, patients with late treatment initiation had lower baseline CD8 level but slower monthly CD8 decline.

Using CD4/CD8 ratio as the marker of immune recovery, the monthly change of the ratio was 0.01 from treatment initiation. The baseline CD4/CD8 among middle-aged and elderly was lower than the young adults. Comparing with young adults, middle-aged had slower CD4/CD8 ratio recovery rate while elderly had similar rate. Patients with positive baseline CMV serology had lower ratio at baseline. Male and patients on NNRTI-based regimen had slower CD4/CD8 ratio increase over time than their counterparts. Also, CD4/CD8 ratio recovery of patients in late diagnosis, with late treatment initiation and who had a long interval from diagnosis to treatment initiation was faster, even though the baseline of those in late diagnosis and late treatment initiation was lower.
Figure 1. Scattered plots of (a) CD4 count, (b) CD8 count, and (c) CD4/CD8 ratio over time (months from HAART initiation) with linear regression lines, stratified by age categories (18-49 years old, 50-64 years old, ≥65 years old)
Discussion

Our study findings highlighted the association of age category at treatment initiation with the pattern and pace of immune recovery of HIV patients after HAART. This is an important perspective in HIV treatment now that more patients are entering older age. In our cohort, the immune recovery of middle-aged adult Chinese was significantly slower than young adults, but their CD4 recovery was faster than the elderly. Of note, our findings identified slower CD8 decline in the middle-aged compared to elderly, making middle-aged the age category with the slowest recovery of CD4/CD8 ratio. Besides age, we also identified late diagnosis and late treatment initiation as the predictors of CD4 recovery, while NNRTI, male gender and baseline CMV as the predictors of CD8 decline. All of these were predictors of CD4/CD8 ratio recovery. While elderly people are long known to be performing less favourably in immune recovery, our results reminded us of the unique challenges faced by the middle-aged.

While late diagnosis and treatment initiation were significant predictors of CD4 and CD4/CD8 ratio recovery, they were significantly associated with age category. Both middle-aged and elderly were more likely to be in late HIV diagnosis and treatment initiation, an observation consistent with other studies. Elderly people had lower perceived risk of HIV infection and were more likely to ignore the symptomatology of HIV/AIDS, which may appear to be similar with other common chronic illnesses. With delayed HIV diagnosis, they were therefore more likely to be late for treatment initiation, as shown by the low CD4 level at diagnosis in Table 1 and 2.

In addition to the well-known impact of age on CD4 recovery as reported in studies locally and internationally, we observed that these responses varied between late and non-late treatment initiation. Middle-aged adults in late treatment initiation had faster CD4 recovery than elderly. However, the difference of the two age categories in non-late treatment initiation was not obvious. Though age at treatment initiation was a known significant predictor for CD4 recovery, aging during treatment (the duration on treatment and increasing age during treatment) were not associated with CD4 decline in the first 5 years of treatment. These results suggested that, compared to aging during treatment, pre-treatment age might have bigger impact on CD4 recovery after treatment initiation. The variation of immune recovery rate by pre-treatment age category and/or late treatment initiation observed in our study lends support to this phenomenon. While the interval from HIV infection to treatment initiation might affect the age at which treatment begins, the implications for late HIV diagnosis and treatment initiation would need to be addressed separately. Late diagnosis demands effective public health intervention such as testing scaling up, while late treatment initiation could be addressed by developing appropriate health service strategy. A study has concluded that older patients would have higher benefits under early treatment initiation strategy, even though their definition of elderly differed from ours.
Although most studies had used CD4 as a marker for immune recovery, CD8 and CD4/CD8 ratio should not be ignored in view of their association with chronic inflammation and immune activation.17-19 Expressing the pace of immune recovery by CD4/CD8 ratio, the rate of change after treatment initiation in middle-aged patients in our study was slowest compared to other age categories. Our results on CD4/CD8 ratio change were slightly different from another study.20 In the latter study, older patients were more likely to have inverted CD4/CD8 ratio (<0.9) and less likely to have CD4/CD8 normalization. Continuous age variable was used instead of classifying middle-aged as one category, which might have smoothed the sudden drop of CD4/CD8 ratio recovery rate in middle-aged over the whole age range. On the other hand, we found that CMV was a significant predictor of CD8 and CD4/CD8 ratio, but not CD4. Even though we used baseline CMV serostatus as predictor, our finding was consistent with another study examining the association of CMV serostatus with CD8 and CD4/CD8 ratio.21,22

Our study carries some limitations. First, in the absence of a universal standard for “middle-age”, we acknowledge that defining it as 50-64 years-old might be arbitrary even though our approach has taken reference from other related studies.9,17 We performed sensitivity analyses (results not shown) to assess the impact of varying this definition for age category. The variables significantly associated with age categories were similar when the definition was changed in sensitivity analysis, except CMV serostatus, which became different if patients aged 40-45 was grouped as middle-aged. Second, because of small sample size of non-Chinese patients and high variation of CD4 level by ethnic population,10,12 the temporal change of immune recovery markers were examined among Chinese patients only. While such an approach carried an advantage of minimizing the impact of ethnic heterogeneity of the studied population, the results could theoretically be applicable to Chinese HIV patients only, and caution must be exercised when extrapolating results to other ethnicities. Third, we are also mindful of the cautious use of nevirapine (NVP), when NNRTI-based regimens were considered for women and those with high CD4 count.23,24 We have performed a set of GEE models examining NNRTI as a factor with the exclusion of all time points with NVP (results not shown) but could not find any significant difference. Fourth,
limited by data availability, the characterization of immune recovery was limited to markers of CD4, CD8 and CD4/CD8 ratio only.

Finally, with the generally higher mortality rate of elderly HIV patients compared to the young adults, the former was often regarded as the group in urgent need of treatment. Our results showed that while a high proportion of elderly (age above 65) were in late HIV diagnosis, their current treatment initiation status was in fact close to “immediate”. On the contrary, the immune recovery of middle-aged in our cohort was far from satisfactory after treatment initiation. Whereas middle-aged adults were slightly faster than elderly in their rate of CD4 recovery, their CD4/CD8 ratio recovery was even slower. As middle-aged were less likely to be in late diagnosis than the elderly, we believe that they have not been initiated treatment as early as that for the elderly, especially in time of a CD4-guided approach to treatment initiation. The middle-aged patients would have a better immune response if they had been initiated treatment earlier, i.e. when they were younger, or even at the age of young adults. Treat All is a new recommendation of WHO, a strategy just started but not yet fully implemented in places like Hong Kong. As a proportion of patients diagnosed in early years might not have been initiated on treatment due to various reasons, there is the need to focus on those with unmet need because of poorer anticipated outcome. Interventions for improving treatment uptake of middle-aged HIV patients should be prioritised to maximize the benefits of the strategy.
References


1. Which of the following observations is generally true about treatment and age of HIV infected patients?
   (a). Young patients tend to have lower risk of viral rebound while on treatment
   (b). Old patients tend to require more potent highly active antiretroviral therapy for successful viral suppression
   (c). Final clinical outcome is independent of age
   (d). Old patients tend to have poorer immune recovery
   (e). None of the above

2. In this cohort study of HIV infected patients in Hong Kong, middle-aged patients are defined as those aged
   (a). 30-49 years
   (b). 40-49 years
   (c). 40-54 years
   (d). 50-64 years

3. In this study, treatment initiation is not considered late when
   (a). CD4 count is <200 cells/μL but ≥100 cells/μL
   (b). CD4 count is <100 cells/μL
   (c). AIDS-defining illness has occurred with a CD4 count < 200 cells/μL
   (d). AIDS-defining illness has occurred with a CD4 count ≥ 200 cells/μL
4. Which of the following is associated with late treatment initiation?
(a) Injecting drug use
(b) Middle-aged at diagnosis
(c) Elderly at diagnosis
(d) Heterosexually acquired infections
(e) All of the above

5. Comparing to young patients, middle-aged patients are more likely to be
(a) Chinese
(b) Heterosexual
(c) Having a lower CD4 at diagnosis
(d) AIDS patients
(e) All of the above

6. Which of the following is true regarding CD4 count with treatment?
(a) CD4 cell count rebounds in first 6 months, and then plateaus
(b) CD4 cell count rebounds most rapidly in young patients
(c) CD4 cell count rebounds most rapidly in middle-aged patients
(d) CD4 cell count rebounds more rapidly with NNRTI-based regimen
(e) None of the above

7. Which of the following is false regarding immune recovery with treatment?
(a) Age category is a significant factor
(b) NNRTI-based regimen, rather than PI-based regimen, is a favourable factor of immune recovery
(c) Late treatment initiation has impact on immune recovery
(d) Late diagnosis is a significant factor
(e) None of the above

8. Which of the following is generally true regarding CD4, CD8 and CD4/CD8 ratio?
(a) With effective treatment, CD4 will rise, CD8 will drop, and CD4/CD8 will rise
(b) With effective treatment, CD4 will rise, CD8 will rise, and CD4/CD8 will drop
(c) With effective treatment, CD4 will fall and then rise, CD8 will drop and then rise, and CD4/CD8 will be stable
(d) With effective treatment, CD4 will rise and then fall, CD8 will drop, and CD4/CD8 will continue to rise
(e) There is no consistent pattern with effective treatment

9. Which of the following is true regarding middle-aged patients in this cohort?
(a) Middle-aged patients were more likely to be diagnosed late than young patients
(b) Middle-aged patients had slower recovery of CD4/CD8 ratio than elderly patients because of a slower decline of CD8
(c) Middle-aged patients had slower recovery of CD4 count than young patients
(d) Middle-aged patients had faster recovery of CD4 count than elderly patients
(e) All of the above

10. Which of the following is reasonable inference from this study?
(a) Progressively more potent therapy should be used as a patient ages during treatment
(b) Treatment should be initiated early as late treatment initiation is associated with relatively poor immune recovery
(c) NNRTI-based regimen is preferred to PI-based regimen
(d) As middle-aged patients experience the slowest recovery of CD4/CD8, it is reasonable to defer therapy for a middle-aged patient until the CD4 count drops below 200 cells/uL
(e) None of the above